Trigonelline
(Synonyms: 胡芦巴碱; Trigenolline) 目录号 : GN10289
Trigonelline是一种从Trigonella foenum-graecum L或Leonurus artemisia中分离出来的生物碱，是一种强效且特异性的Nrf2抑制剂。
Cas No.:535-83-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Trigonelline, an alkaloid isolated from Trigonella foenum-graecum L or Leonurus artemisia, is a potent and specific inhibitor of Nrf2[1]. Nrf2 (nuclear factor erythroid 2–related factor 2) is the master transcriptional regulator of cellular antioxidant defense, eliminating reactive oxygen species and maintaining redox homeostasis by up-regulating genes such as HO-1 and NQO1[2]. Trigonelline is widely used in research related to anti-diabetes, anti-oxidation, anti-inflammation and neuroprotection by blocking NrF2-dependent proteasome activity[3][4].
In vitro, pretreatment of H9c2 cells with Trigonelline (25-125µM; 24h) before H₂O₂ stimulation significantly rescued cell morphology, attenuated H₂O₂-induced cell deaths, enhanced antioxidant activity, down-regulated the expression of apoptotic genes (caspase-3, caspase-9), and up-regulated the expression of anti-apoptotic genes (Bcl-2, Bcl-XL)[5]. Trigonelline (0.1-1mM; 16h) significantly inhibited Nrf2 activity in pancreatic cancer cell lines (Panc1, Colo357, MiaPaca2) and H6c7 pancreatic duct cells, reduced nuclear Nrf2 levels and proteasome activity, and enhanced cell sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and etoposide-induced apoptosis, increasing caspase-3/7 activity by 2.3-4.3 fold[6].
In vivo, Trigonelline (10mg/kg/day; i.p.; 14 days) reversed silica-induced pulmonary fibrosis, reduced the expression of fibrotic markers (such as Collagen 1 and Fibronectin) in lung tissues, inhibited fibroblast-to-myofibroblast differentiation by repressing TGF-β/Smad signaling, and improved fibrotic pathological features in a silica-induced pulmonary fibrosis mouse model[7].
References:
[1] Nguyen V, Taine EG, Meng D, Cui T, Tan W. Pharmacological Activities, Therapeutic Effects, and Mechanistic Actions of Trigonelline. Int J Mol Sci. 2024;25(6):3385.
[2] Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):721-733.
[3] Ozçelik B, Kartal M, Orhan I. Cytotoxicity, antiviral and antimicrobial activities of alkaloids, flavonoids, and phenolic acids. Pharm Biol. 2011;49(4):396-402.
[4] Su Y, Zhao B, Zhou L, et al. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 2020;483:127-136.
[5] Ilavenil S, Kim DH, Jeong YI, et al. Trigonelline protects the cardiocyte from hydrogen peroxide induced apoptosis in H9c2 cells. Asian Pac J Trop Med. 2015;8(4):263-268.
[6] Arlt A, Sebens S, Krebs S, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2013;32(40):4825-4835.
[7] Zhang F, Yue H, Dong R, et al. Trigonelline hydrochloride attenuates silica-induced pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation. Respir Res. 2024;25(1):242.
Trigonelline是一种从Trigonella foenum-graecum L或Leonurus artemisia中分离出来的生物碱，是一种强效且特异性的Nrf2抑制剂[1]。Nrf2（核因子E2相关因子2）是细胞抗氧化防御的主要转录调控因子，通过上调HO-1和NQO1等基因的表达清除活性氧并维持氧化还原稳态[2]。Trigonelline通过阻断Nrf2依赖的蛋白酶体活性，广泛应用于抗糖尿病、抗氧化、抗炎和神经保护等相关研究[3][4]。
在体外实验中，在H₂O₂ 刺激前用Trigonelline（25-125µM；24小时）预处理H9c2细胞可显著改善细胞形态，减轻H₂O₂ 诱导的细胞死亡，增强抗氧化活性，下调凋亡基因（caspase-3、caspase-9）的表达，并上调抗凋亡基因（Bcl-2、Bcl-XL）的表达[5]。Trigonelline（0.1-1mM；16小时）显著抑制胰腺癌细胞系（Panc1、Colo357、MiaPaca2）和H6c7胰腺导管细胞中的Nrf2活性，降低核内Nrf2水平和蛋白酶体活性，并增强细胞对肿瘤坏死因子相关的凋亡诱导配体（TRAIL）和依托泊苷诱导凋亡的敏感性，使caspase-3/7活性增加了 2.3-4.3 倍[6]。
在体内实验中，在二氧化硅诱导的肺纤维化小鼠模型中，Trigonelline（10mg/kg/天；腹腔注射；14天）逆转了二氧化硅诱导的肺纤维化，降低了肺组织中纤维化标志物（如胶原蛋白1和纤维连接蛋白）的表达，通过抑制TGF-β/Smad信号通路抑制了成纤维细胞向肌成纤维细胞的分化，并改善了纤维化病理特征[7]。
| Cell experiment [1]: | |
Cell lines | H9c2 cells |
Preparation Method | The H9c2 cell line, derived from embryonic BD1X rat heart tissue were cultured in Dulbecco’s Modified Eagle’s Medium containing 4mM L-glutamine, 4500mg/L glucose, 1mM sodium pyruvate, and 1500mg/L sodium bicarbonate. Cells were treated with different concentration of trigonelline(25-125µM) for 24h and then cells were harvested. The harvested cells were detected with Annexin V-FITC/PI Apoptosis method. |
Reaction Conditions | 25-125μM; 24h |
Applications | Trigonelline significantly attenuated H₂O₂-induced cell deaths. |
| Animal experiment [2]: | |
Animal models | Wild-type C57BL/6 mice |
Preparation Method | The male, and of wild-type C57BL/6 background 8–10 weeks old were bred in the Specific Pathogen-Free Laboratory Animal Center. The SiO2-induced fibrosis model involved randomly dividing mice into four groups: (1) PBS+PBS group, (2) PBS+Trigonelline (10mg/kg) group, (3) SiO2+PBS group, and (4) SiO2+Trigonelline(10mg/kg) group. SiO2 (200mg/kg in 50mg/mL PBS) or PBS was administered for endotracheal Perfusion. The starting day of the model was designated as day 1. Starting on day 28, mice in the PBS+Trig (10mg/kg) group and SiO2+Trigonelline group were administered Trig (10mg/kg) intraperitoneally for 14 consecutive days. Meanwhile, mice in the SiO2+PBS group and the PBS+PBS group received an equal amount of PBS. On day 42, the mice were euthanized to analyze the pulmonary fibrosis phenotype. |
Dosage form | 10mg/kg/day; i.p.; 14 days |
Applications | Trigonelline reversed silica-induced pulmonary fibrosis, and improved fibrotic pathological features in a silica-induced pulmonary fibrosis mouse model. |
References: | |
| Cas No. | 535-83-1 | SDF | |
| 别名 | 胡芦巴碱; Trigenolline | ||
| 化学名 | 1-methylpyridin-1-ium-3-carboxylate | ||
| Canonical SMILES | C[N+]1=CC=CC(=C1)C(=O)[O-] | ||
| 分子式 | C7H7NO2 | 分子量 | 137.05 |
| 溶解度 | Insoluble in EtOH; ≥26 mg/mL in Water; ≥8.5 mg/mL in DMSO | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 7.2966 mL | 36.483 mL | 72.9661 mL |
| 5 mM | 1.4593 mL | 7.2966 mL | 14.5932 mL |
| 10 mM | 0.7297 mL | 3.6483 mL | 7.2966 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet